2. Search Result
Search Result
Results for "

and melanoma

" in MedChemExpress (MCE) Product Catalog:

714

Inhibitors & Agonists

6

Fluorescent Dyes

12

Biochemical Assay Reagents

71

Peptides

68

Inhibitory Antibodies

126

Natural
Products

24

Isotope-Labeled Compounds

2

Click Chemistry

17

Oligonucleotides

2

GMP Molecules

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-125860
    Tyrosinase, Mushroom

    Polyphenol oxidase

    		 Tyrosinase Neurological Disease Endocrinology Cancer
    Tyrosinase (EC 1.14.18.1) (Polyphenol oxidase) is a rate-limiting enzyme that controls the production of melanin. Tyrosinase is mainly found in melanosomes synthesized by skin melanocytes. Tyrosinase can be used in research on Parkinson's disease, melanoma and pigmentation .
    Tyrosinase, Mushroom
  • HY-N0610A
    Cinnamic acid
    3 Publications Verification

    3-Phenylacrylic acid; β-Phenylacrylic acid

    		 Environmental Pollutants Endogenous Metabolite Cancer
    Cinnamic acid has potential use in cancer intervention, with IC50s of 1-4.5 mM in glioblastoma, melanoma, prostate and lung carcinoma cells.
    Cinnamic acid
  • HY-P9978
    Toripalimab

    JS-001

    		 PD-1/PD-L1 Cancer
    Toripalimab is a selective, recombinant, humanized monoclonal antibody against PD-1. Toripalimab is able to bind to PD-1 and block the interaction with its ligands. Toripalimab has exhibited primary anti-tumor effects in tumors such as melanoma, lung cancer, digestive tract tumors, hepatobiliary and pancreatic tumors, neuroendocrine neoplasms, nasopharyngeal carcinoma and urothelial carcinoma .
    Toripalimab
  • HY-168374
    DSPE-PEG2000-Mannose
    1 Publications Verification

    		 Biochemical Assay Reagents Liposome Small Interfering RNA (siRNA) Cancer
    DSPE-PEG 2000-Mannose is a mannose-containing lipid. DSPE-PEG 2000-Mannose is used to prepare mannose-conjugated Liposome (Man-lipo) for siRNA delivery. Mannose-modified liposomes encapsulating IDO siRNA (Man-lipo-siIDO) preferentially knock down IDO expression in the draining lymph nodes and spleens of melanoma-bearing mice. Man-lipo-siIDO delays the onset time of melanoma and reduces tumor volume .
    DSPE-PEG2000-Mannose
  • HY-N0202
    Atractylenolide II
    3 Publications Verification

    Asterolide

    		 ERK Apoptosis p38 MAPK Akt Src STAT Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    Atractylenolide II (Asterolide) is a sesquiterpenoid compound. Atractylenolide II can induce G1 phase cell cycle arrest and apoptosis in B16 melanoma cells. Atractylenolide II is an orally effective anticancer agent that can exert anti-melanoma effects by inhibiting the STAT3 signaling pathway. In addition, Atractylenolide II has been shown to ameliorate myocardial fibrosis, oxidative stress, and neuroprotective activity .
    Atractylenolide II
  • HY-113107
    3-Hydroxydodecanoic acid

    		Endogenous Metabolite Cancer
    3-Hydroxydodecanoic acid is a medium-chain fatty acid. 3-Hydroxydodecanoic acid activates GPR84 and promotes IL-12 production. 3-Hydroxydodecanoic acid has anticancer activity against colon cancer, lung cancer, and melanoma .
    3-Hydroxydodecanoic acid
  • HY-122506
    Salviolone

    		STAT Cancer
    Salviolone is a natural diterpenoid derivative that can against melanoma cells. Salviolone exhibits a pleiotropic effect against melanoma by hampering cell cycle progression, STAT3 signaling, and malignant phenotype of A375 melanoma cells .
    Salviolone
  • HY-N7085
    Citropten

    5,7-Dimethoxycoumarin; Limettin

    		 Environmental Pollutants ERK p38 MAPK JNK Neurological Disease Inflammation/Immunology Cancer
    Citropten (5, 7-dimethoxycoumarin) is one of the coumarin derivatives. Citropten is an effective oral anticancer agent. Citropten has anti-proliferative activity against A2058 and B16 melanoma cells. Citropten exerts anti-inflammatory effects through the NFκB and MAPK signaling pathways. Citropten acts as an antidepressant through heat shock protein-70, monoamine oxidase-A and inhibition of apoptosis .
    Citropten
  • HY-B0455
    Lomefloxacin hydrochloride

    SC47111A hydrochloride; NY-198 hydrochloride

    		 Antibiotic Bacterial Topoisomerase Reactive Oxygen Species (ROS) Apoptosis Infection Endocrinology Cancer
    Lomefloxacin hydrochloride (NY-198 hydrochloride) is an orally active difluoroquinolone antibiotic. Lomefloxacin hydrochloride prevents DNA supercoiling and replication by inhibiting bacterial topoisomerase II. Lomefloxacin hydrochloride induces ROS production and Apoptosis. Lomefloxacin hydrochloride has broad-spectrum bactericidal activity against Gram-positive and Gram-negative bacteria. Lomefloxacin hydrochloride has anticancer effects against melanoma. Lomefloxacin hydrochloride can be used in the study of systemic bacterial infections (such as Salmonella typhimurium infections), skin and melanoma .
    Lomefloxacin hydrochloride
  • HY-156483
    TT-012
    2 Publications Verification

    		 Microphthalmia Associated Transcription Factor (MITF) Cancer
    TT-012 is a MITF inhibitor with a human MITF IC50 of 13.1 nM and a human MITF Kd value of 15.5 nM. TT-012 reduces mRNA levels of MITF downstream genes linked to melanosome biogenesis, cell survival, and proliferation, and upregulates cell cycle-inhibiting genes. TT-012 can be used for the research of melanoma[1][2][3].
    TT-012
  • HY-126330
    SS-208

    AVS100

    		 HDAC Cancer
    SS-208 is a selective HDAC6 inhibitor, with an IC50 of 12 nM. SS-208 possesses anti-tumor activity in melanoma .
    SS-208
  • HY-N3023
    3,4-Dihydroxybenzylamine hydrobromide
    1 Publications Verification

    NSC 263475 hydrobromide

    		 DNA/RNA Synthesis Cancer
    3,4-Dihydroxybenzylamine hydrobromide (NSC 263475 hydrobromide) is an improved dopamine analog cytotoxic and inhibits DNA polymerase activity in melanoma cells . 3,4-Dihydroxybenzylamine hydrobromide (NSC 263475 hydrobromide) displays growth inhibitory activity in melanoma cell lines with varying degrees of tyrosinase activity .
    3,4-Dihydroxybenzylamine hydrobromide
  • HY-108533
    CD2314

    		RAR/RXR Cancer
    CD2314 is a potent and selective RARβ receptor agonist with a Kd of 195 nM in S91 melanoma cells .
    CD2314
  • HY-P2336A
    CCZ01048 TFA
    3 Publications Verification

    		 Melanocortin Receptor Cancer
    CCZ01048 TFA, a α-MSH analogue, exhibits high binding affinity to melanocortin 1 receptor (MC1R) with a Ki of 0.31 nM. CCZ01048 TFA shows rapid internalization into B16F10 melanoma cells and high in vivo stability. CCZ01048 TFA is a promising candidate for PET imaging of malignant melanoma .
    CCZ01048 TFA
  • HY-100948
    ATM-3507

    		Myosin Cancer
    ATM-3507 is a potent tropomyosin inhibitor with IC50s from 3.83-6.84 μM in human melanoma cell lines.
    ATM-3507
  • HY-B0455A
    Lomefloxacin

    SC47111A; NY-198

    		 Bacterial Antibiotic Topoisomerase Reactive Oxygen Species (ROS) Apoptosis Infection
    Lomefloxacin (SC47111A) is an orally active difluoroquinolone antibiotic. Lomefloxacin prevents DNA supercoiling and replication by inhibiting bacterial topoisomerase II. Lomefloxacin induces ROS production and Apoptosis. Lomefloxacin has broad-spectrum bactericidal activity against Gram-positive and Gram-negative bacteria. Lomefloxacin has anticancer effects against melanoma. Lomefloxacin can be used in the study of systemic bacterial infections (such as Salmonella typhimurium infections), skin and melanoma .
    Lomefloxacin
  • HY-148511
    Vidutolimod

    CMP-001

    		 Toll-like Receptor (TLR) IFNAR PD-1/PD-L1 Indoleamine 2,3-Dioxygenase (IDO) Cancer
    Vidutolimod (CMP-001) is a virus-like particle containing a TLR9 activator . Vidutolimod induces human peripheral blood mononuclear cells to secrete IFNα, and upregulates the gene expression of CXCL10, PDL1, IDO and CD80. Vidutolimod activates TLR9, which in turn triggers plasmacytoid dendritic cell activation, production of IFNγ and TNFα, induction of CXCL10, and recruitment of antitumor T cells. Vidutolimod causes influenza-like symptoms, hypotension and tumor regression, and its activity depends on the presence of anti-Qβ antibodies. Vidutolimod modulates monocyte function, promotes CD4 T cell proliferation, and activates multiple immune cell types in an environment with anti-Qβ antibodies. Vidutolimod prolongs the survival of tumor-bearing mice. Vidutolimod is used in research related to advanced melanoma, head and neck squamous cell carcinoma, and advanced non-small cell lung cancer .
    Vidutolimod
  • HY-P11288
    ANT308

    		PACAP Receptor Apoptosis Cancer
    ANT308 is a vasoactive intestinal polypeptide (VIP receptor) antagonist. ANT308 significantly enhances the activation and proliferation of T cells. ANT308 inhibits the migration and metastasis, induces apoptosis of melanoma tumor cells by inhibiting VIP-VPAC2 signaling and reducing the expression of MCAM and N-cadherin. ANT308 can be used for the studies of acute myeloid leukemia (AML) and uveal melanoma (UVM) .
    ANT308
  • HY-P11288A
    ANT308 TFA

    		PACAP Receptor Apoptosis Cancer
    ANT308 TFA is a vasoactive intestinal polypeptide (VIP receptor) antagonist. ANT308 TFA significantly enhances the activation and proliferation of T cells. ANT308 TFA inhibits the migration and metastasis, induces apoptosis of melanoma tumor cells by inhibiting VIP-VPAC2 signaling and reducing the expression of MCAM and N-cadherin. ANT308 TFA can be used for the study of acute myeloid leukemia (AML) and uveal melanoma (UVM) .
    ANT308 TFA
  • HY-161767
    JWJ-01-306

    		Molecular Glues Oxidative Phosphorylation Ras Cancer
    JWJ-01-306 is a CRBN-recruiting ZBTB11 Molecular Glues degrader. JWJ-01-306 degrades ZBTB11 and reprograms cellular metabolism, thereby reducing the level of Oxidative Phosphorylation and the activity of the tricarboxylic acid cycle. JWJ-01-306 enhances the response of organoids to K-Ras inhibition. JWJ-01-306 inhibits the proliferation of pancreatic ductal adenocarcinoma cells and melanoma cells. JWJ-01-306 can be used in studies related to pancreatic ductal adenocarcinoma and melanoma .
    JWJ-01-306
  • HY-177120
    DMBP

    		Autophagy Cancer
    DMBP is a VPS41 inhibitor. DMBP induces methuosis and inhibits autophagy in cancer cells. DMBP inhibits the fusion of late endosomes and autophagosomes with lysosomes. DMBP effectively inhibits metastasis in a mouse metastatic melanoma model. DMBP can be used for the study of melanoma .
    DMBP
  • HY-149380
    Vem-L-Cy5

    		Raf Cancer
    Vem-L-Cy5 (compound 3)，modified with the NIR fluorophore cyanine-5 (Cy5)，is a Vemurafenib (HY-12057)-based inhibitor of BRAF. Vem-L-Cy5 targets to BRAF V600E，and also inhibits MEK phosphorylation. Vem-L-Cy5 has cell permeability，and inhibits cell growth of many types of cancer .
    Vem-L-Cy5
  • HY-134963
    SBI-0087702

    		PKC Cancer
    SBI-0087702 promots the cytoplasmic localization of ATF2 in melanoma cells. SBI-0087702-induced translocation of ATF2 to the mitochondria results in increased apoptosis due to loss of mitochondrial membrane integrity. SBI-0087702 also inhibits growth and motility of melanoma cells. SBI-0087702 was shown to inhibit ATF2 phosphorylation on Thr52 by PKCε .
    SBI-0087702
  • HY-115712
    DHPS-IN-1
    1 Publications Verification

    		 DNA/RNA Synthesis Cancer
    DHPS-IN-1, with the best DHPS inhibitory potency (IC50 = 0.014 μM), exhibits excellent inhibition against melanoma cells.
    DHPS-IN-1
  • HY-W272217S
    Octacosane-d58

    n-Octacosane-d58; NSC 5549-d58

    		 Bacterial Endogenous Metabolite Cancer
    Octacosane-d58 is the deuterium labeled Octacosane . Octacosane is an endogenous metabolite with antibacterial activity. Octacosane shows high cytotoxicity against murine melanoma B16F10-Nex2 cells besides inducing protection against a grafted subcutaneous melanoma. Octacosane has the larvicidal activity against mosquito Culex quinquefasciatus with the LC50 concentration of 7.2 mg/l .
    Octacosane-d58
  • HY-W272217
    Octacosane

    n-Octacosane; NSC 5549

    		 Endogenous Metabolite Bacterial Inflammation/Immunology Cancer
    Octacosane is an endogenous metabolite with antibacterial activity. Octacosane shows high cytotoxicity against murine melanoma B16F10-Nex2 cells besides inducing protection against a grafted subcutaneous melanoma. Octacosane has the larvicidal activity against mosquito Culex quinquefasciatus with the LC50 concentration of 7.2 mg/l .
    Octacosane
  • HY-150534
    Anti-melanoma agent 1

    		Apoptosis Cancer
    Anti-melanoma agent 1 (Compound 5m) is an anti-melanoma agent and induces cell apoptosis .
    Anti-melanoma agent 1
  • HY-179717
    WZS0347

    		PROTACs Microphthalmia Associated Transcription Factor (MITF) Cancer
    WZS0347 is a MITF PROTAC degrader. WZS0347 effectively reduces the MITF protein levels in several melanoma cell lines, including B16F10, A375, and GAK. WZS0347 significantly inhibits the proliferation, migration, and invasion of melanoma cells. WZS0347 can be used for research on melanoma (Pink: MITF ligand: (HY-179718); Blue: CRBN ligand: (HY-131717); Black: linker: (HY-22391)) .
    WZS0347
  • HY-P2336
    CCZ01048

    		Melanocortin Receptor Cancer
    CCZ01048, a α-melanocyte-stimulating hormone (α-MSH) analogue, exhibits high binding affinity to melanocortin 1 receptor (MC1R) with a Ki of 0.31 nM. CCZ01048 shows rapid internalization into B16F10 melanoma cells and high in vivo stability. CCZ01048 is a promising candidate for PET imaging of malignant melanoma .
    CCZ01048
  • HY-N11108
    Gochnatiolide A

    		Others Cancer
    Gochnatiolide A is a dimeric sesquiterpene that can be found in Ainsliaea henryi. Gochnatiolide A exhibits antiproliferative activity against the kidney, melanoma, ovarian-resistant and glioma cell lines .
    Gochnatiolide A
  • HY-175298
    STAT-3/c-Src-IN-1

    		STAT Src Apoptosis Cancer
    STAT-3/c-Src-IN-1 (Compound 12d) is a dual STAT-3 (IC50=0.844 μM) and c-Src (IC50=0.268 μM) inhibitor. STAT-3/c-Src-IN-1 blocks tumor cell proliferation, migration, and angiogenesis signaling pathways. STAT-3/c-Src-IN-1 exhibits potent anti-proliferative activity against melanoma (SK-MEL-2) and CNS cancer (SNB-75) cell lines (GI50=-5.75 μM and -5.63 μM), inducing tumor cell apoptosis via G0/G1 and G2/M phase cell cycle arrest. STAT-3/c-Src-IN-1 is promising for research of melanoma and glioblastoma .
    STAT-3/c-Src-IN-1
  • HY-W654372
    Tigloyl-L-carnitine chloride

    		Endogenous Metabolite Cancer
    Tigloyl-L-carnitine (chloride) is a short-chain acylacarnitine containing tiglic acid and L-carnitine. Tigloyl-L-carnitine (chloride) is increased in plasma in certain melanoma xenograft murine models. Tigloyl-L-carnitine (chloride) can be studied in research on melanoma .
    Tigloyl-L-carnitine chloride
  • HY-111604
    Turbinaric acid

    		Others Cancer
    Turbinaric acid is a kind of secosqualene carboxylic acid. Turbinaric acid exhibits cytotoxicity against mouse melanoma cells and human colon cancer cells. Turbinaric acid can be used as a chemical marker for T. conoides. Turbinaric acid can be used for research on melanoma and colon cancer .
    Turbinaric acid
  • HY-P2939
    Chondroitinase AC

    		Apoptosis Biochemical Assay Reagents Cancer
    Chondroitinase AC is a hydrolytic enzyme. Chondroitinase AC degrades chondroitin sulfate A and chondroitin sulfate C. Chondroitinase AC inhibits the invasion and proliferation of melanoma cells and endothelial cells, and increases apoptosis. Chondroitinase AC can be used in research on melanoma and other cancers .
    Chondroitinase AC
  • HY-P11424
    Cyclo(GRGDSPA)

    		Integrin Cancer
    Cyclo(GRGDSPA) is a cyclic RGD peptide targeting αvβ3 integrin. Cyclo(GRGDSPA) reduces the formation of colonies in mice injected with B16-FE7 melanoma cells. Cyclo(GRGDSPA) can be used for melanoma research .
    Cyclo(GRGDSPA)
  • HY-150639
    Everafenib

    		Raf Cancer
    Everafenib is a potent and blood-brain barrier (BBB) penetrant BRAF inhibitor, also inhibits MAPK signaling. Everafenib has inhibitory activity against a panel of V600EBRAF melanoma cell lines with IC50 values of 2-10 nM, which is better than Dabrafenib (HY-14660) and Vemurafenib (HY-12057). Everafenib has efficacy in an intracranial mouse model of metastatic melanoma .
    Everafenib
  • HY-B0078S
    Dacarbazine-d6

    Imidazole Carboxamide-d6

    		 Nucleoside Antimetabolite/Analog Apoptosis Cancer
    Dacarbazine-d6 is the deuterium labeled Dacarbazine. Dacarbazine(DTIC-Dome; DTIC) is an antineoplastic agent. It has significant activity against melanomas.
    Dacarbazine-d6
  • HY-100948B
    ATM-3507 trihydrochloride

    		Myosin Cancer
    ATM-3507 trihydrochloride is a potent tropomyosin inhibitor with IC50s from 3.83-6.84 μM in human melanoma cell lines.
    ATM-3507 trihydrochloride
  • HY-P11293
    DOTA-GGNle-CycMSHhex

    		Melanocortin Receptor Cancer
    DOTA-GGNle-CycMSHhex is a melanocortin-1 receptor (MC1R)-targeting peptide that can be radionuclide-labeled for melanoma imaging .
    DOTA-GGNle-CycMSHhex
  • HY-10615
    A-620223
    1 Publications Verification

    		 PARP Cancer
    A-620223 is a PARP-1 inhibitor with a Ki of 8 nM against PARP-1 and EC50 of 3 nM in a whole cell assay. A-620223 demonstrates good in vivo efficacy in a B16F10 subcutaneous murine melanoma model in combination with Temozolomide (TMZ) (HY-17364) and in an MX-1 breast xenograph model in combination with Cisplatin (HY-17394). A-620223 can be used for the studies of melanoma and breast cancer .
    A-620223
  • HY-120066
    Seriniquinone

    		Autophagy Cancer
    Seriniquinone, a selective anti-melanoma agent that targets Dermcidin, induces cell death by autophagocytosis. Seriniquinone is a metabolite produced by a rare marine bacterium of the genus Serinicoccus .
    Seriniquinone
  • HY-144868
    Glutathione synthesis-IN-1

    		Glutathione S-transferase Cancer
    Glutathione synthesis-IN-1 is an orally active radiosensitizer and intracellular glutathione synthesis inhibitor. Glutathione synthesis-IN-1 can be used in the research of melanoma and glioma .
    Glutathione synthesis-IN-1
  • HY-178995
    BRAFV600E-IN-3

    		Raf Cancer
    BRAFV600E-IN-3 (Compound AV05) is a BRAF V600E inhibitor with an IC50 value of 0.89 μM. BRAFV600E-IN-3 inhibits the proliferation of melanoma cells. BRAFV600E-IN-3 can be used for the study of melanoma .
    BRAFV600E-IN-3
  • HY-149497
    HDAC6-IN-19

    		HDAC Cancer
    HDAC6-IN-19 (Compound 14g) is a HDAC6 inhibitor (IC50: 2.68 nM). HDAC6-IN-19 also inhibits HDAC1, HDAC2 and HDAC3 with IC50s of 61.6 nM, 98.7 nM and 103 nM. HDAC6-IN-19 potently inhibits multiple cancer cell proliferation, including leukemia, colon cancer, melanoma, and breast cancer cell lines .
    HDAC6-IN-19
  • HY-133846
    Iodothiouracil

    		Thyroid Hormone Receptor Cancer
    Iodothiouracil exhibits high selectivity for melanoma, remains stable in the melanin in melanoma cells, and localizes remote secondary metastases of melanoma. Iodothiouracil can be used for melanoma imaging when labeled with iodine-123, and can be used for radiation therapy when labeled with iodine-131 .
    Iodothiouracil
  • HY-161340
    Anti-melanoma agent 2

    		Apoptosis Cancer
    Anti-melanoma agent 2 (Compound IId) is a steroid hybrid that effectively induces endoplasmic reticulum stress (ERS) and causes apoptosis. Anti-melanoma agent 2 shows anti-melanoma effects .
    Anti-melanoma agent 2
  • HY-119427
    Anti-melanoma agent 3

    		Microtubule/Tubulin Cancer
    Anti-melanoma agent 3 (compound 5cb) is a 2-aryl-4-benzoyl-imidazole (ABI) derivative and an inhibitor of melanoma xenogeneic tumors. Anti-melanoma agent 3 exerts anticancer activity by interacting with the colchicine binding site to inhibit tubulin polymerization .
    Anti-melanoma agent 3
  • HY-149950
    Anticancer agent 106

    		Apoptosis Cancer
    Anticancer agent 106 (compound 10ic) is an anticancer agent that induces apoptosis in B16-F10 melanoma cells. Anticancer agent 106 also potently inhibits metastatic nodules in a mouse model of lung metastatic melanoma. Anticancer agent 106 can be used in the study of cancer, especially lung metastatic melanoma .
    Anticancer agent 106
  • HY-P1796A
    Gp100 (619-627) acetate

    		Transmembrane Glycoprotein Cancer
    Gp100 (619-627) acetate is amino acids 619 to 627 fragment of human melanoma antigen glycoprotein 100 (gp100). Gp100 has been a widely studied target for melanoma immunotherapy .
    Gp100 (619-627) acetate
  • HY-149949
    Anticancer agent 105

    		Apoptosis Cancer
    Anticancer agent 105 is a compound based on thienopyrimidine scaffold, with with good safety and anticancer properties. Anticancer agent 105 shows selective toxicity towards melanoma cancer, and induces apoptosis. And Anticancer agent 105 significantly inhibits the metastatic nodules, even in pulmonary metastatic melanoma mouse model .
    Anticancer agent 105

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: